RU2010149312A - ТЕРАПЕВТИЧЕСКИ ПОЛЕЗНЫЕ ЗАМЕЩЕННЫЕ ГИДРОПИРИДО [3,2,1-ij] ХИНОЛИНОВЫЕ СОЕДИНЕНИЯ - Google Patents
ТЕРАПЕВТИЧЕСКИ ПОЛЕЗНЫЕ ЗАМЕЩЕННЫЕ ГИДРОПИРИДО [3,2,1-ij] ХИНОЛИНОВЫЕ СОЕДИНЕНИЯ Download PDFInfo
- Publication number
- RU2010149312A RU2010149312A RU2010149312/04A RU2010149312A RU2010149312A RU 2010149312 A RU2010149312 A RU 2010149312A RU 2010149312/04 A RU2010149312/04 A RU 2010149312/04A RU 2010149312 A RU2010149312 A RU 2010149312A RU 2010149312 A RU2010149312 A RU 2010149312A
- Authority
- RU
- Russia
- Prior art keywords
- hydrocarbon radical
- group
- radical containing
- hydroxyalkyl
- alkylcarbonyl
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract 88
- 229930195733 hydrocarbon Natural products 0.000 claims abstract 88
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 32
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 31
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 31
- 239000001257 hydrogen Substances 0.000 claims abstract 31
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 30
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract 30
- 125000005843 halogen group Chemical group 0.000 claims abstract 30
- 125000003118 aryl group Chemical group 0.000 claims abstract 29
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims abstract 29
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 28
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 28
- 125000005842 heteroatom Chemical group 0.000 claims abstract 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 26
- 125000005157 alkyl carboxy group Chemical group 0.000 claims abstract 21
- 229910052736 halogen Inorganic materials 0.000 claims abstract 21
- 150000002367 halogens Chemical class 0.000 claims abstract 21
- 125000003277 amino group Chemical group 0.000 claims abstract 19
- -1 alkylamide Chemical group 0.000 claims abstract 17
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims abstract 17
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 13
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000001301 oxygen Substances 0.000 claims abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract 3
- 239000011593 sulfur Substances 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims 24
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 7
- 150000004677 hydrates Chemical class 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 230000035876 healing Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000032544 Cicatrix Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 230000037387 scars Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038886 Retinal oedema Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000006218 bradycardia Diseases 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 1
- 201000011195 retinal edema Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 0 *CCCNC(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O Chemical compound *CCCNC(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O 0.000 description 2
- XZBUULMEXZUZKI-UHFFFAOYSA-N C=CCCOC(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O Chemical compound C=CCCOC(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O XZBUULMEXZUZKI-UHFFFAOYSA-N 0.000 description 1
- QZHCREZZXWMEDS-UHFFFAOYSA-N CC(C)(CC1)c2cc(NC(OC)=O)cc3c2N1CCC3(C)C Chemical compound CC(C)(CC1)c2cc(NC(OC)=O)cc3c2N1CCC3(C)C QZHCREZZXWMEDS-UHFFFAOYSA-N 0.000 description 1
- QCRUNQLJDABFOC-UHFFFAOYSA-N CCC1(C)c(cc(cc2C(C)CC3)NC(OC)=O)c2N3CC1 Chemical compound CCC1(C)c(cc(cc2C(C)CC3)NC(OC)=O)c2N3CC1 QCRUNQLJDABFOC-UHFFFAOYSA-N 0.000 description 1
- LCKRDYRQUPOWOD-UHFFFAOYSA-N CCCCC(Nc1cc(C(C)(CC2)c3ccccc3)c3N2CCC(C)(c2ccccc2)c3c1)=O Chemical compound CCCCC(Nc1cc(C(C)(CC2)c3ccccc3)c3N2CCC(C)(c2ccccc2)c3c1)=O LCKRDYRQUPOWOD-UHFFFAOYSA-N 0.000 description 1
- YZYMLLIJVAWGOX-QBHOUYDASA-N CCCCOC(Nc(cc1[C@@H](CC2)c3cccc(C)c3)cc3c1N2CCC3c1cc(C)ccc1)=O Chemical compound CCCCOC(Nc(cc1[C@@H](CC2)c3cccc(C)c3)cc3c1N2CCC3c1cc(C)ccc1)=O YZYMLLIJVAWGOX-QBHOUYDASA-N 0.000 description 1
- NDSDRWUQGQFISK-DTQAZKPQSA-N CCCOC(N/C=C/c1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O Chemical compound CCCOC(N/C=C/c1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O NDSDRWUQGQFISK-DTQAZKPQSA-N 0.000 description 1
- JYIHZGHEHOKLOZ-IBGZPJMESA-N CCCSC(Nc1cc(CCC2)c3N2CC[C@@H](c2ccccc2)c3c1C)=O Chemical compound CCCSC(Nc1cc(CCC2)c3N2CC[C@@H](c2ccccc2)c3c1C)=O JYIHZGHEHOKLOZ-IBGZPJMESA-N 0.000 description 1
- OKBPVNFRQFNRPH-UHFFFAOYSA-N CN(C)C(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O Chemical compound CN(C)C(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O OKBPVNFRQFNRPH-UHFFFAOYSA-N 0.000 description 1
- SMYPACKMYDWVIY-UHFFFAOYSA-N COC(Nc1cc(C(CC2)c3c[s]cc3)c3N2CCC(c2c[s]cc2)c3c1)=O Chemical compound COC(Nc1cc(C(CC2)c3c[s]cc3)c3N2CCC(c2c[s]cc2)c3c1)=O SMYPACKMYDWVIY-UHFFFAOYSA-N 0.000 description 1
- JHZSBCOBNNGRPH-UHFFFAOYSA-N CSC(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O Chemical compound CSC(Nc1cc(C(CC2)c3ccccc3)c3N2CCC(c2ccccc2)c3c1)=O JHZSBCOBNNGRPH-UHFFFAOYSA-N 0.000 description 1
- PINYLGIYLJXQNA-UHFFFAOYSA-N Cc1ccc(C(CC2)c3c4N2CCC(c2c(C)cc(C)cc2)c4cc(NC(OCC#C)=O)c3)c(C)c1 Chemical compound Cc1ccc(C(CC2)c3c4N2CCC(c2c(C)cc(C)cc2)c4cc(NC(OCC#C)=O)c3)c(C)c1 PINYLGIYLJXQNA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5153308P | 2008-05-08 | 2008-05-08 | |
| US61/051,533 | 2008-05-08 | ||
| US12/433,978 | 2009-05-01 | ||
| US12/433,978 US20090281322A1 (en) | 2008-05-08 | 2009-05-01 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010149312A true RU2010149312A (ru) | 2012-06-20 |
Family
ID=40863539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010149312/04A RU2010149312A (ru) | 2008-05-08 | 2009-05-07 | ТЕРАПЕВТИЧЕСКИ ПОЛЕЗНЫЕ ЗАМЕЩЕННЫЕ ГИДРОПИРИДО [3,2,1-ij] ХИНОЛИНОВЫЕ СОЕДИНЕНИЯ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090281322A1 (OSRAM) |
| EP (1) | EP2294069B1 (OSRAM) |
| JP (1) | JP5432246B2 (OSRAM) |
| CN (1) | CN102089306A (OSRAM) |
| AU (1) | AU2009244199B2 (OSRAM) |
| BR (1) | BRPI0912534A2 (OSRAM) |
| CA (1) | CA2723798A1 (OSRAM) |
| IL (1) | IL209200A0 (OSRAM) |
| RU (1) | RU2010149312A (OSRAM) |
| WO (1) | WO2009137681A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013024657A2 (pt) * | 2011-03-25 | 2016-12-20 | Allergan Inc | antagonistas da s1p como hipotensivos oculares adjuntos |
| KR101691954B1 (ko) | 2016-04-26 | 2017-01-02 | 고려대학교 산학협력단 | 신규 n-아실유레아 유도체 및 이를 함유하는 심혈관질환의 예방 또는 치료용 조성물 |
| CN107369775B (zh) * | 2017-07-13 | 2018-12-25 | 长春海谱润斯科技有限公司 | 一种有机电致发光材料及其有机发光器件 |
| CN107492597B (zh) * | 2017-08-10 | 2018-11-27 | 长春海谱润斯科技有限公司 | 一种顶发射有机发光器件 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005519915A (ja) * | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| AU2003263413A1 (en) * | 2002-09-17 | 2004-04-08 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
| US20040131648A1 (en) * | 2002-10-24 | 2004-07-08 | The Procter & Gamble Company | Nuclear hormone receptor compounds, products and methods employing same |
| US20040167185A1 (en) * | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associated with an Edg-3 receptor |
| EP2298770A1 (en) * | 2005-11-03 | 2011-03-23 | ChemBridge Corporation | Heterocyclic compounds as TrkA modulators |
| WO2007112322A2 (en) * | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
-
2009
- 2009-05-01 US US12/433,978 patent/US20090281322A1/en not_active Abandoned
- 2009-05-07 CN CN2009801266353A patent/CN102089306A/zh active Pending
- 2009-05-07 BR BRPI0912534A patent/BRPI0912534A2/pt not_active IP Right Cessation
- 2009-05-07 WO PCT/US2009/043149 patent/WO2009137681A1/en not_active Ceased
- 2009-05-07 AU AU2009244199A patent/AU2009244199B2/en not_active Ceased
- 2009-05-07 EP EP09743667.9A patent/EP2294069B1/en not_active Not-in-force
- 2009-05-07 RU RU2010149312/04A patent/RU2010149312A/ru not_active Application Discontinuation
- 2009-05-07 JP JP2011508667A patent/JP5432246B2/ja not_active Expired - Fee Related
- 2009-05-07 CA CA2723798A patent/CA2723798A1/en not_active Abandoned
-
2010
- 2010-11-08 IL IL209200A patent/IL209200A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0912534A2 (pt) | 2015-10-13 |
| JP2011527286A (ja) | 2011-10-27 |
| EP2294069A1 (en) | 2011-03-16 |
| JP5432246B2 (ja) | 2014-03-05 |
| CN102089306A (zh) | 2011-06-08 |
| IL209200A0 (en) | 2011-01-31 |
| EP2294069B1 (en) | 2015-09-02 |
| AU2009244199B2 (en) | 2013-09-19 |
| AU2009244199A1 (en) | 2011-10-06 |
| US20090281322A1 (en) | 2009-11-12 |
| WO2009137681A1 (en) | 2009-11-12 |
| CA2723798A1 (en) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6994538B2 (ja) | 医薬化合物 | |
| AU2015239886B2 (en) | Indole derivatives for use in medicine | |
| JP2019094345A5 (OSRAM) | ||
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2017043614A5 (OSRAM) | ||
| AU2016336437A1 (en) | Compounds, compositions, and methods for modulating CFTR | |
| JP2018515495A5 (OSRAM) | ||
| JP2018535963A5 (OSRAM) | ||
| JP6970691B2 (ja) | Ｔｒｐｖ４拮抗薬 | |
| JP2016519685A5 (OSRAM) | ||
| CA2793311A1 (en) | Modulators of hec1 activity and methods therefor | |
| JP2007016011A (ja) | 抗酸化活性を有する新規な含窒素ヘテロ環化合物、及び該化合物を含有する抗酸化薬 | |
| NZ597453A (en) | Fluorinated aminotriazole derivatives as alxr agonists | |
| US20180044331A1 (en) | Piperazine derivatives for treating disorders | |
| RU2010143455A (ru) | Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов | |
| JP2014524465A5 (OSRAM) | ||
| JP2021535112A5 (OSRAM) | ||
| JP5781093B2 (ja) | 新たな置換イソキノリン誘導体 | |
| RU2018124591A (ru) | Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение | |
| DK2611415T3 (en) | ADENOSIN-A1 AGONISTS FOR TREATMENT OF GLAUCUMA AND OCULAR HYPERTENSION | |
| ES2749657T3 (es) | Derivados de O-alquil-bencilidenguanidina y su uso terapéutico para el tratamiento de trastornos asociados a una acumulación de proteínas mal plegadas | |
| JP2020535172A (ja) | Ｓｒｐｋ１阻害剤 | |
| JP2025108537A (ja) | 近視を治療するための化合物、組成物及び医薬組成物 | |
| WO2013077579A1 (ko) | 안과 질환의 예방 및 치료용 약학 조성물 | |
| RU2013130022A (ru) | Новые бензиловые производные азетидина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20120608 |